Abstract
PurposeChemotherapy-induced peripheral neuropathy (CIPN) commonly affects people treated for cancer, with functional consequences of impaired balance and falls. Virtual reality technology (VR) may be able to assess balance, identifying patients at increased risk of falls. We aimed to assess the impact of neurotoxic chemotherapy on balance and falls risk using VR, and explore whether changes in balance threshold were associated with falls or validated CIPN measures. MethodsWe conducted a prospective, longitudinal cohort study at two Australian oncology centres. Eligible participants were commencing adjuvant chemotherapy containing a taxane for breast cancer, or oxaliplatin for colon cancer. Excluded: insufficient English to complete assessments, VR intolerance, or pre-existing balance disorder. VR balance threshold was recorded at baseline, intervals during chemotherapy, and 3- and 6-months after chemotherapy completion. Additional measures: 1) clinician-graded peripheral sensory neuropathy (Common Terminology Criteria for Adverse Events), 2) Total Neuropathy Score-clinical, 3) patient-reported neuropathy, 4) ‘Timed Up-and-Go’ test, 5) participant-reported falls/near-falls. ResultsOf 34 participants consented, 24 (71%) had breast cancer and 10 (29%) had colon cancer. Compared to baseline, balance threshold worsened in 10/28 (36%) evaluable participants assessed at the end-of-chemotherapy; this persisted in 7/22 (32%) at 6 months. CIPN affected 86% at end of chemotherapy, and 73% at 6-months post-chemotherapy . Falls/near-falls were reported by 12/34 (35%), and associated with impaired balance (p = 0.002). ConclusionVR balance assessment warrants further investigation as a surrogate method to objectively identify patients at risk of falls from CIPN, however was no better at diagnosing CIPN than existing tools. Trial Registration: N/A